Merit Medical Systems Inc
NASDAQ:MMSI
Merit Medical Systems Inc
Merit Medical Systems Inc. stands as a hallmark of innovation and precision in the medical device industry. Founded in 1987, this Utah-based company has carved a niche by developing and manufacturing a diverse range of products designed to enhance the ability of physicians and improve patient care. Merit's operations focus on the production of disposable medical devices catering primarily to the fields of interventional cardiology, radiology, endoscopy, and pain management. These products, which include a variety of catheters, microcatheters, embolization coils, and other technical components, are crucial in facilitating minimally invasive procedures that speak to the modern medical demand for efficiency and reduced patient recovery times. The company's relentless pursuit of quality and innovation has spurred consistent growth and expanded its presence globally, illustrating its commitment to meeting the evolving needs of healthcare providers and their patients.
Revenue streams for Merit Medical Systems derive primarily from the sales of these specialized medical devices, accompanied by an expanding portfolio of customer-driven services and support. Unlike many companies that might get mired in a single product line, Merit has strategically diversified its offerings to spread risk and capture a broader segment of the healthcare market. This diversification is reflected in their investment in research and development, enabling the launch of new products regularly, thereby cushioning the company against the volatility typically seen in the medical device sector. The company’s success is a testament to its ability to maintain close relationships with healthcare providers, listening to and fulfilling their complex needs while operating through an intricate web of direct sales representatives and distribution partners globally. This cohesive model fosters both customer loyalty and drives sustainable business growth, ensuring that Merit Medical Systems remains a pivotal player in the evolving landscape of medical technology.
Merit Medical Systems Inc. stands as a hallmark of innovation and precision in the medical device industry. Founded in 1987, this Utah-based company has carved a niche by developing and manufacturing a diverse range of products designed to enhance the ability of physicians and improve patient care. Merit's operations focus on the production of disposable medical devices catering primarily to the fields of interventional cardiology, radiology, endoscopy, and pain management. These products, which include a variety of catheters, microcatheters, embolization coils, and other technical components, are crucial in facilitating minimally invasive procedures that speak to the modern medical demand for efficiency and reduced patient recovery times. The company's relentless pursuit of quality and innovation has spurred consistent growth and expanded its presence globally, illustrating its commitment to meeting the evolving needs of healthcare providers and their patients.
Revenue streams for Merit Medical Systems derive primarily from the sales of these specialized medical devices, accompanied by an expanding portfolio of customer-driven services and support. Unlike many companies that might get mired in a single product line, Merit has strategically diversified its offerings to spread risk and capture a broader segment of the healthcare market. This diversification is reflected in their investment in research and development, enabling the launch of new products regularly, thereby cushioning the company against the volatility typically seen in the medical device sector. The company’s success is a testament to its ability to maintain close relationships with healthcare providers, listening to and fulfilling their complex needs while operating through an intricate web of direct sales representatives and distribution partners globally. This cohesive model fosters both customer loyalty and drives sustainable business growth, ensuring that Merit Medical Systems remains a pivotal player in the evolving landscape of medical technology.
Revenue Beat: Q4 2025 revenue was $393.9 million, up 11% year-over-year, surpassing the high end of guidance.
Profitability: Non-GAAP operating margin rose to 21%, a 138 basis point increase, and non-GAAP EPS grew 12%, both exceeding expectations.
Free Cash Flow: Q4 free cash flow hit a record $74 million, up 13% YoY, and FY25 reached nearly $216 million, well ahead of guidance.
Guidance Raised: 2026 guidance calls for 6%–8% revenue growth, operating margin expansion, and at least $200 million free cash flow.
Product & Segment Drivers: Strong growth in Cardiovascular (up 9%) and Endoscopy (up 15%); Cardiac Intervention sales up 21%.
DualCap Divestiture: The DualCap product line was sold; its absence is a headwind but is expected to free up resources for higher-margin growth.
China & OEM: OEM segment saw weak Q4 due to US inventory destocking and macro softness in China; normalized mid- to high single-digit OEM growth is expected in 2026.
Rhapsody Update: 2026 Rhapsody sales in the US guided to $7 million, with early commercial traction but cautious outlook amid competition.
